NASDAQ:AKUS

Akouos Stock Forecast, Price & News

$13.00

-0.46 (-3.42 %)

(As of 06/11/2021 12:00 AM ET)

Add

Compare

Today's Range

$12.86

▼

$13.38

50-Day Range

$11.87

▼

$15.96

52-Week Range

$11.64

▼

$30.67

Volume95,126 shs

Average Volume181,365 shs

Market Capitalization$447.84 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

30 days | 90 days | 365 days | Advanced Chart

Receive AKUS News and Ratings via Email

Sign-up to receive the latest news and ratings for Akouos and its competitors with MarketBeat's FREE daily newsletter.

About Akouos

Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. Akouos, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

Harvard Business School Announces Its 2021-2022 Blavatnik Fellows - Yahoo Finance
June 2, 2021 | finance.yahoo.com

Head to Head Contrast: Akouos (AKUS) & Its Competitors
May 26, 2021 | americanbankingnews.com

Akouos, Inc. (NASDAQ:AKUS) Given Average Rating of "Buy" by Analysts
May 22, 2021 | americanbankingnews.com

Akouos Reports First Quarter 2021 Financial Results and Provides Business Updates - Yahoo Finance
May 14, 2021 | finance.yahoo.com

Akouos EPS misses by $0.09 - Seeking Alpha
May 13, 2021 | seekingalpha.com

Form 10-Q Akouos, Inc. For: Mar 31 - StreetInsider.com
May 13, 2021 | streetinsider.com

Akouos Reports First Quarter 2021 Financial Results and Provides Business Updates - GlobeNewswire
May 13, 2021 | globenewswire.com

Akouos Reports First Quarter 2021 Financial Results and Provides Business Updates
May 13, 2021 | finance.yahoo.com

'Do you want Tesla to accept Doge?' Musk asks Twitter users - Yahoo Canada Finance
May 11, 2021 | ca.finance.yahoo.com

Akouos (AKUS) Presents Nonclinical Data Supporting Future Clinical Development of AK-OTOF and AK-antiVEGF - StreetInsider.com
May 11, 2021 | streetinsider.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AKUS
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.akouos.com
Phone857-410-1818
Employees69
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$9.03 per share
Price / Book1.44

Profitability

EPS (Most Recent Fiscal Year)($2.77)
Net Income$-48,600,000.00
Net MarginsN/A
Return on Equity-17.21%
Return on Assets-16.05%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares34,449,000
Market Cap$447.84 million
Next Earnings Date8/12/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.57 out of 5 stars

Medical Sector

478th out of 2,096 stocks

Pharmaceutical Preparations Industry

233rd out of 830 stocks

3.4 Analyst's Opinion

Consensus Rating
Akouos has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $30.00, Akouos has a forecasted upside of 130.8% from its current price of $13.00.
Amount of Analyst Coverage
Akouos has only been the subject of 2 research reports in the past 90 days.

2.8 Community Rank

Outperform Votes
Akouos has received 9 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Akouos has received 7 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Akouos has received 56.25% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Akouos and other stocks. Vote “Outperform” if you believe AKUS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AKUS will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Akouos does not currently pay a dividend.
Dividend Growth
Akouos does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Akouos insiders have not sold or bought any company stock.
Percentage Held by Institutions
96.10% of the stock of Akouos is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Akouos are expected to decrease in the coming year, from ($1.97) to ($2.11) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Akouos is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Akouos is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Akouos has a P/B Ratio of 1.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Akouos (NASDAQ:AKUS) Frequently Asked Questions

Is Akouos a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Akouos in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Akouos stock.
View analyst ratings for Akouos or view top-rated stocks.

What stocks does MarketBeat like better than Akouos?

Wall Street analysts have given Akouos a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Akouos wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Akouos' next earnings date?

Akouos is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for Akouos.

How were Akouos' earnings last quarter?

Akouos, Inc. (NASDAQ:AKUS) issued its quarterly earnings results on Wednesday, May, 12th. The company reported ($0.47) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.38) by $0.09.
View Akouos' earnings history.

What price target have analysts set for AKUS?

5 brokerages have issued 12-month price targets for Akouos' stock. Their forecasts range from $20.00 to $40.00. On average, they expect Akouos' stock price to reach $30.00 in the next twelve months. This suggests a possible upside of 130.8% from the stock's current price.
View analysts' price targets for Akouos or view top-rated stocks among Wall Street analysts.

Who are Akouos' key executives?

Akouos' management team includes the following people:

Dr. Emmanuel Simons M.B.A., Ph.D., Co- Founder, Pres, CEO & Director (Age 38, Pay $495.77k)
Dr. Michael John McKenna M.D., Co-Founder, Chief Medical Officer & Member of Scientific Advisory Board (Age 64, Pay $445.08k)
Dr. Gregory Scott Robinson, Chief Scientific Officer (Age 62, Pay $428.02k)
Dr. Luk H. Vandenberghe M.D., Ph.D., Founder & Member of Scientific Advisory Board
Mr. William F. Sewell Ph.D., Founder & Member of Scientific Advisory Board
Mr. Richard Smith M.D., Founder & Member of Scientific Advisory Board
Ms. Sachiyo Minegishi, CFO, Treasurer, Assistant Sec. & Principal Accounting Officer (Age 43)
Ms. Jennifer Anne Wellman, Chief Operating Officer (Age 43)
Dr. Alan K. Smith, Chief Technology Officer (Age 63)
Dr. Karoline K. Shair, Sr. VP, Gen. Counsel, Chief Legal Officer & Corp. Sec.

Who are some of Akouos' key competitors?

Some companies that are related to Akouos include Madrigal Pharmaceuticals (MDGL), Arcus Biosciences (RCUS), Zymeworks (ZYME), Protagonist Therapeutics (PTGX), Applied Molecular Transport (AMTI), Cerevel Therapeutics (CERE), uniQure (QURE), Supernus Pharmaceuticals (SUPN), PureTech Health (PRTC), Aurinia Pharmaceuticals (AUPH), Indivior (INVVY), Constellation Pharmaceuticals (CNST), COMPASS Pathways (CMPS), Y-mAbs Therapeutics (YMAB) and Heron Therapeutics (HRTX).
View all of AKUS's competitors.

What other stocks do shareholders of Akouos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akouos investors own include NVIDIA (NVDA), Honeywell International (HON), QUALCOMM (QCOM), Raytheon Technologies (RTX), CVS Health (CVS), Johnson & Johnson (JNJ), Cisco Systems (CSCO), The Home Depot (HD), Pfizer (PFE) and The Procter & Gamble (PG).

When did Akouos IPO?

(AKUS) raised $124 million in an initial public offering on Friday, June 26th 2020. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Cowen and Piper Sandler acted as the underwriters for the IPO and BTIG was co-manager.

What is Akouos' stock symbol?

Akouos trades on the NASDAQ under the ticker symbol "AKUS."

Who are Akouos' major shareholders?

Akouos' stock is owned by many different institutional and retail investors. Top institutional investors include Federated Hermes Inc. (7.29%), BlackRock Inc. (5.80%), Citadel Advisors LLC (3.92%), Geode Capital Management LLC (1.01%), Northern Trust Corp (0.68%) and Caas Capital Management LP (0.67%).

Which institutional investors are selling Akouos stock?

AKUS stock was sold by a variety of institutional investors in the last quarter, including Caas Capital Management LP, Millennium Management LLC, Morgan Stanley, Citadel Advisors LLC, Victory Capital Management Inc., Citigroup Inc., and Ensign Peak Advisors Inc.

Which institutional investors are buying Akouos stock?

AKUS stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Federated Hermes Inc., JPMorgan Chase & Co., Geode Capital Management LLC, Mercer Global Advisors Inc. ADV, Envestnet Asset Management Inc., Northern Trust Corp, and Nuveen Asset Management LLC.

How do I buy shares of Akouos?

Shares of AKUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Akouos' stock price today?

One share of AKUS stock can currently be purchased for approximately $13.00.

How much money does Akouos make?

Akouos has a market capitalization of $447.84 million. The company earns $-48,600,000.00 in net income (profit) each year or ($2.77) on an earnings per share basis.

How many employees does Akouos have?

Akouos employs 69 workers across the globe.

What is Akouos' official website?

The official website for Akouos is www.akouos.com.

Where are Akouos' headquarters?

Akouos is headquartered at 645 SUMMER STREET SUITE 200, BOSTON MA, 02210.

How can I contact Akouos?

Akouos' mailing address is 645 SUMMER STREET SUITE 200, BOSTON MA, 02210. The company can be reached via phone at 857-410-1818 or via email at [email protected]

This page was last updated on 6/12/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here